This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Parr, C. Articles by Jiang, W. G. Search for Related Content PubMed PubMed Citation Articles by Parr, C. Articles by Jiang, W. G.

The Hepatocyte Growth Factor Regulatory Factors in Human Breast Cancer

Metastasis Research Group, University Department of Surgery, University of Wales College of Medicine, Cardiff, United Kingdom

Purpose: Hepatocyte growth factor (HGF) stimulates tumor cell-cell interactions, matrix adhesion, migration, invasion, and angiogenesis. This factor is produced as an inactive precursor called pro-HGF, which requires proteolytic conversion, by HGF activator (HGFA) and matriptase, to evoke a biological response. Two new HGFA inhibitors, HAI-1 and HAI-2, inhibit the generation of biologically active HGF, through their interaction with HGFA. This study determined the expression of this HGF regulatory system in breast cancer. We examined HGF, the HGF receptor (c-Met), HGFA, matriptase, and the activation inhibitors (HAI-1 and HAI-2), tissues from patients with breast cancer.

Experimental Design: Breast cancer tissue (n = 100) and normal background tissue (n = 20) was obtained immediately after surgery. The median follow-up for the patients was 72 months. HGF, c-Met, HGFA, matriptase-1, HAI-1, and HAI-2 expression was quantified using real-time quantitative PCR. The distribution of these factors in mammary tissues was also examined through immunohistochemistry.

Results: The breast cancer specimens expressed a significantly higher level of HGF, c-Met, HGFA, HAI-1, and HAI-2, but not matriptase, compared with the normal background tissues. Tumor tissues from node-positive patients expressed a higher level of HGFA than from the patients without nodal involvement. Interestingly, HAI-2 was expressed to a lower degree in positive nodes than that of the node-negative breast cancer tissues. HAI-1 and HAI-2 were both significantly reduced in grade 3 tumors compared with the well-differentiated tumors. In addition, on comparison of Tumor-Node-Metastasis (TNM) classification groups, HAI-2 was also found to be statistically lower in the TNM 3 breast cancer group when compared with TNM groups 1 and 2, thus associated with a poor prognosis.

Conclusions: This study shows that there are aberrant levels of HGF, c-Met, HGFA, HAI-1, and HAI-2 expressed in breast cancer tissues compared with background breast tissue. HAI-1 and HAI-2 are expressed to a significantly lower level in poorly differentiated breast tumors, and HAI-2 is also inversely correlated with nodal involvement and tumor spread. Overall a low level of HAI-2 in the breast cancer tissues was associated with an overall poor outlook. Therefore, the HGF regulatory system may have an important role in the progression of breast cancer.

This article has been cited by other articles:

				K. NAKAMURA, A. HONGO, J. KODAMA, F. ABARZUA, Y. NASU, H. KUMON, and Y. HIRAMATSU Expression of Matriptase and Clinical Outcome of Human Endometrial Cancer Anticancer Res, May 1, 2009; 29(5): 1685 - 1690. [Abstract] [Full Text] [PDF]

				P. N. Kongkham, P. A. Northcott, Y. S. Ra, Y. Nakahara, T. G. Mainprize, S. E. Croul, C. A. Smith, M. D. Taylor, and J. T. Rutka An Epigenetic Genome-Wide Screen Identifies SPINT2 as a Novel Tumor Suppressor Gene in Pediatric Medulloblastoma Cancer Res., December 1, 2008; 68(23): 9945 - 9953. [Abstract] [Full Text] [PDF]

				R. Szabo, J. P. Hobson, K. List, A. Molinolo, C.-Y. Lin, and T. H. Bugge Potent Inhibition and Global Co-localization Implicate the Transmembrane Kunitz-type Serine Protease Inhibitor Hepatocyte Growth Factor Activator Inhibitor-2 in the Regulation of Epithelial Matriptase Activity J. Biol. Chem., October 24, 2008; 283(43): 29495 - 29504. [Abstract] [Full Text] [PDF]

				A. K. Sasser, N. J. Sullivan, A. W. Studebaker, L. F. Hendey, A. E. Axel, and B. M. Hall Interleukin-6 is a potent growth factor for ER-{alpha}-positive human breast cancer FASEB J, November 1, 2007; 21(13): 3763 - 3770. [Abstract] [Full Text] [PDF]

				C. Parr, A. J. Sanders, G. Davies, T. Martin, J. Lane, M. D. Mason, R. E. Mansel, and W. G. Jiang Matriptase-2 Inhibits Breast Tumor Growth and Invasion and Correlates with Favorable Prognosis for Breast Cancer Patients Clin. Cancer Res., June 15, 2007; 13(12): 3568 - 3576. [Abstract] [Full Text] [PDF]

				D. Generali, S. B. Fox, A. Berruti, J. W. Moore, M. P. Brizzi, N. Patel, G. Allevi, S. Bonardi, S. Aguggini, A. Bersiga, et al. Regulation of Hepatocyte Growth Factor Activator Inhibitor 2 by Hypoxia in Breast Cancer Clin. Cancer Res., January 15, 2007; 13(2): 550 - 558. [Abstract] [Full Text] [PDF]

				O. K. Hallikas, J. M. Aaltonen, H. von Koskull, L.-A. Lindberg, L. Valmu, N. Kalkkinen, T. Wahlstrom, H. Kataoka, L. Andersson, D. Lindholm, et al. Identification of Antibodies against HAI-1 and Integrin {alpha}6{beta}4 as Immunohistochemical Markers of Human Villous Cytotrophoblast J. Histochem. Cytochem., July 1, 2006; 54(7): 745 - 752. [Abstract] [Full Text] [PDF]

				W. G. Jiang, A. Raz, A. Douglas-Jones, and R. E. Mansel Expression of Autocrine Motility Factor (AMF) and Its Receptor, AMFR, in Human Breast Cancer J. Histochem. Cytochem., February 1, 2006; 54(2): 231 - 241. [Abstract] [Full Text] [PDF]

				A. Bertotti, P. M. Comoglio, and L. Trusolino {beta}4 Integrin Is a Transforming Molecule that Unleashes Met Tyrosine Kinase Tumorigenesis Cancer Res., December 1, 2005; 65(23): 10674 - 10679. [Abstract] [Full Text] [PDF]

				B. S. Knudsen, J. M. Lucas, L. Fazli, S. Hawley, S. Falcon, I. M. Coleman, D. B. Martin, C. Xu, L. D. True, M. E. Gleave, et al. Regulation of Hepatocyte Activator Inhibitor-1 Expression by Androgen and Oncogenic Transformation in the Prostate Am. J. Pathol., July 1, 2005; 167(1): 255 - 266. [Abstract] [Full Text] [PDF]

				P. C. Ma, R. Jagadeeswaran, S. Jagadeesh, M. S. Tretiakova, V. Nallasura, E. A. Fox, M. Hansen, E. Schaefer, K. Naoki, A. Lader, et al. Functional Expression and Mutations of c-Met and Its Therapeutic Inhibition with SU11274 and Small Interfering RNA in Non-Small Cell Lung Cancer Cancer Res., February 15, 2005; 65(4): 1479 - 1488. [Abstract] [Full Text] [PDF]